CCH Injections Could Be Option for Acute-Phase Peyronie's Disease
World Meeting: Abstract Deadline is November 1
Injections of collagenase Clostridium histolyticum (CCH) have been approved for the treatment of stable-phase Peyronie's disease. Now, new research suggests that they might be appropriate for the acute phase as well.
The acute phase is marked by the formation of plaques on the penis, which causes a distinct curvature and, for some men, pain. Once these symptoms stabilize, patients are in the stable stage of disease.
In a Journal of Sexual Medicine study, researchers compared data from 162 men in the acute and stable phases who underwent CCH therapy.
Most men, regardless of Peyronie's stage, saw improvements in curvature with no side effects. More research is needed to confirm these results, however.
Further information on the study, including a description of the treatment process and the authors' views on why CCH injections were effective for men in the acute phase, please click here.
Thinking about submitting an abstract for the World Meeting on Sexual Medicine? The deadline will be here soon!
The Scientific Committee will accept abstract submissions for podium, poster, and video presentations until November 1, 2017. See the details here.
All abstracts presented at the meeting will be published in the Journal of Sexual Medicine. They will also be eligible to compete for prestigious prizes.
The World Meeting on Sexual Medicine will be held in Lisbon, Portugal February 28 – March 3, 2018.